Singapore markets closed
  • Straits Times Index

    3,200.26
    +27.26 (+0.86%)
     
  • Nikkei

    29,357.82
    +26.45 (+0.09%)
     
  • Hang Seng

    28,610.65
    -26.81 (-0.09%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • BTC-USD

    59,294.95
    +3,553.33 (+6.37%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow

    34,777.76
    +229.23 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.39 (+0.88%)
     
  • Gold

    1,832.00
    +16.30 (+0.90%)
     
  • Crude Oil

    64.82
    +0.11 (+0.17%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • FTSE Bursa Malaysia

    1,587.45
    +9.12 (+0.58%)
     
  • Jakarta Composite Index

    5,928.31
    -41.93 (-0.70%)
     
  • PSE Index

    6,258.71
    -24.07 (-0.38%)
     

Oncology/Cancer Drugs Market to Reach $222.38 Bn by 2027 at 7.4% CAGR

Allied Market Research
·5-min read

Increase in incidence of cancer across the globe and rise in global geriatric population, drive the growth of the global oncology/cancer Drugs market.

Portland, OR, April 20, 2021 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2027” According to the report, the global oncology/cancer Drugs industry generated $128.35 billion in 2019, and is expected to reach $222.38 billion by 2027, witnessing a CAGR of 7.4% from 2020 to 2027.

Prime determinants of growth

Increase in incidence of cancer across the globe, rise in global geriatric population, and surge in government expenditure on healthcare drive the growth of the global oncology/cancer drugs market. However, adverse effect associated with the use of cancer drugs hinder the market growth. Contrarily, high growth potential in untapped emerging economies and increase in number of pipeline drugs present new opportunities in the coming years.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/121

Covid-19 Scenario:

  • The outbreak of Coronavirus disease (COVID-19) has significantly impacted the oncology/cancer drugs market, as the supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across several countries.

  • In addition, COVID 19 has disrupted the most crucial areas of the oncology/cancer drugs market by distorting clinical trials and drug supply chains. COVID-19’s interference with the research and development of new treatments is one of the most significant blows to the cancer drugs market.

The targeted therapy segment to continue its leadership status during the forecast period

Based on drug class, the targeted therapy segment held the highest share in 2019, accounting for nearly three-fifths of the global oncology/cancer drugs market, and is projected to continue its leadership status during the forecast period. This is attributed to the identification of molecular targets of cancer cells, fewer adverse effects, and availability of number of targeted therapeutics. On the other hand, the immunotherapy segment is estimated to portray the highest CAGR of 9.9% from 2020 to 2027.

The breast cancer segment offers lucrative opportunities

Based on indication, the breast cancer segment accounted for the largest market share in 2019, contributing to nearly one-fourth of the global oncology/cancer drugs market, and is expected to maintain its lead position during the forecast period. On the other hand, the lung cancer segment is projected to register the highest CAGR of 9.6% from 2020 to 2027. This is owing to higher incidence, increase in geriatric population, changes in lifestyle of people, and rise in smoking of tobacco which includes passive smoking, which may lead to lung cancer.

North America to maintain its dominance in terms of revenue by 2027

Based on region, North America contributed to the highest share in 2019, holding nearly half of the global oncology/cancer drugs market, and is estimated to maintain its dominance in terms of revenue by 2027. However, the Asia-Pacific region is expected to witness the fastest CAGR of 9.4% from 2020 to 2027. This is due owing to increase in number of cancer affected population and rise in awareness related to different cancers.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/121

Leading market players

  • AbbVie Inc. Amgen

  • Astellas Pharma Inc.

  • AstraZeneca PLC

  • Bristol-Myers Squibb Company

  • F. Hoffmann-La Roche Ltd.

  • Johnson & Johnson (Janssen Global Services, LLC,)

  • Merck & Co., Inc.

  • Novartis AG, and Pfizer Inc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.

Other Trending Reports:

Immuno-oncology Assay Market -Global Opportunity Analysis and Industry Forecast, 2019–2026

China Oncology Drugs Market - Opportunity Analysis and Industry Forecast, 2019-2026

Digital PCR Market :Opportunity Analysis and Industry Forecast, 2020–2027

Brain Monitoring Market -Global Opportunity Analysis and Industry Forecast, 2018-2025

Ultra-Large Volume Wearable Injectors Market : Global Opportunity Analysis and Industry Forecast, 2019–2026

Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market-Global Opportunity Analysis and Industry Forecast, 2020–2027

Blood Bank Market - Global Opportunity Analysis and Industry Forecast, 2020–2027

Healthcare IT Market - U.S. Opportunity Analysis and Industry Forecast, 2017 - 2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

CONTACT: Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research